93
(cont'd)
1
Monitor adherence and
response to therapy
NO
YES
2a
Add inclisiran* to
lower LDL-C
Patient unable to tolerate,
obtain, or adhere to
PCSK9 mAb therapy?
2a
Optional apoB goals
1
If goal not achieved, add
reduced-dose statin
(if tolerated), bempedoic acid,
ezetimibe, and/or PCSK9 mAb
AND
With clinical ASCVD
* Cardiovascular outcomes for inclisiran pending results of ongoing RCTs.
ASCVD indicates atherosclerotic cardiovascular disease; CAC, coronary artery calcium; FDA, US
Food and Drug Administration; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density
lipoprotein-cholesterol; LLT, lipid-lowering therapy; mAb, monoclonal antibody; and PCSK9,
proprotein convertase subtilisin/kexin type 9.
